TomoHD(TM) Radiation Therapy System Selected by UCSF Medical Center
02 Mai 2011 - 2:00PM
Marketwired
TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced
radiation therapy solutions for the treatment of cancer and other
diseases, today announced that University of California, San
Francisco (UCSF) Medical Center has purchased a TomoTherapy®
TomoHD™ treatment system. Upon installation later this year, UCSF
Medical Center will become the first treatment center using the
TomoTherapy treatment platform in San Francisco. UCSF Medical
Center ranks among the nation's top 10 premier hospitals according
to U.S. News & World Report's 2010-11 America's Best Hospitals
survey.
"At UCSF, we are on a mission to provide the optimal treatment
for every cancer case we treat," said Dr. Mack Roach, professor,
Radiation Oncology and Urology at UCSF. "Our state-of-the-art
arsenal of radiation therapy solutions helps us ensure that our
patients have access to the very best, and most appropriate,
treatment available anywhere in the world."
The TomoHD system enables clinicians to accurately and
efficiently treat tumors throughout the body with advanced
image-guided, intensity-modulated radiation therapy (IG-IMRT)
capabilities. The system's integrated imaging and treatment
delivery capabilities provide an improved workflow for treating
large field tumors, as well as prostate and head and neck cancers,
among others.
"We are very pleased to offer cutting-edge radiation therapy
solutions to patients," said Fred Robertson, M.D., TomoTherapy's
president and CEO. "Adoption of the TomoHD treatment system
provides clinicians with a flexible and efficient option for
delivering high quality treatments to a wide range of tumors."
About TomoTherapy Incorporated TomoTherapy Incorporated
develops, markets and sells advanced radiation therapy solutions
that can be used to treat a wide variety of cancers, from the most
common to the most complex. The ring gantry-based TomoTherapy®
platform combines integrated CT imaging with conformal radiation
therapy to deliver sophisticated radiation treatments with speed
and precision while reducing radiation exposure to surrounding
healthy tissue. TomoTherapy's suite of solutions include its
Hi-Art® treatment system, which has been used to deliver more than
three million CT-guided, helical intensity-modulated radiation
therapy (IMRT) treatment fractions; the TomoHD™ treatment system,
designed to enable cancer centers to treat a broader patient
population with a single device; and the TomoMobile™ relocatable
radiation therapy solution, designed to improve access and
availability of state-of-the-art cancer care. TomoTherapy's stock
is traded on the NASDAQ Global Select Market under the symbol TOMO.
To learn more about TomoTherapy, please visit TomoTherapy.com.
UC Disclaimer The information stated above
was prepared by TomoTherapy and reflects solely the opinion of the
corporation. Nothing in this statement shall be construed to imply
any support or endorsement of TomoTherapy, or any of its products,
by The Regents of the University of California, its officers,
agents and employees.
©2011 TomoTherapy Incorporated. All rights reserved.
TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi-Art
are among trademarks, service marks or registered trademarks of
TomoTherapy Incorporated in the United States and other
countries.
Investor Contact: Thomas E. Powell Chief Financial
Officer 608.824.2800 Email Contact Media Contacts: Kevin
O'Malley Director, Corporate Communications 608.824.3384 Email
Contact Susan Lehman Rockpoint Public Relations 510.832.6006 Email
Contact
Tom Online (NASDAQ:TOMO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Tom Online (NASDAQ:TOMO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024